Literature DB >> 8298644

Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.

S Park1, A Bernard, K E Bove, D A Sens, D J Hazen-Martin, A J Garvin, D A Haber.   

Abstract

Nephrogenic rests consist of foci of primitive renal cells, typically microscopic, that are found within the normal kidney tissue of children with Wilms' tumour. To study the relationship between nephrogenic rests and the associated tumours, we screened these lesions for mutations in the 11p13 Wilms' tumour suppressor gene, WT1. In two cases in which the Wilms' tumour contained a somatic WT1 mutation, the nephrogenic rest had the identical mutation. Nephrogenic rests and Wilms' tumours are therefore topographically distinct lesions that are clonally derived from an early renal stem cell. Inactivation of WT1 appears to be an early genetic event which can lead to the formation of nephrogenic rests, enhancing the probability that additional genetic hits will lead to Wilms' tumour.

Entities:  

Mesh:

Year:  1993        PMID: 8298644     DOI: 10.1038/ng1293-363

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  32 in total

1.  Glypican 3 overexpression in primary and metastatic Wilms tumors.

Authors:  Maria Tretiakova; Debra L Zynger; Chunyan Luan; Nicole K Andeen; Laura S Finn; Masha Kocherginsky; Bin T Teh; Ximing J Yang
Journal:  Virchows Arch       Date:  2014-11-04       Impact factor: 4.064

2.  Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children.

Authors:  Masayuki Haruta; Yasuhito Arai; Naoki Watanabe; Yuiko Fujiwara; Shohei Honda; Junjiro Ohshima; Fumio Kasai; Hisaya Nakadate; Hiroshi Horie; Hajime Okita; Jun-Ichi Hata; Masahiro Fukuzawa; Yasuhiko Kaneko
Journal:  Cancer Sci       Date:  2012-04-19       Impact factor: 6.716

3.  Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors.

Authors:  Raisa Vuononvirta; Neil J Sebire; Anthony R Dallosso; Jorge S Reis-Filho; Richard D Williams; Alan Mackay; Kerry Fenwick; Anita Grigoriadis; Alan Ashworth; Kathy Pritchard-Jones; Keith W Brown; Gordan M Vujanic; Chris Jones
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

4.  Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.

Authors:  Ryuji Fukuzawa; Rosemary W Heathcott; Helen E More; Anthony E Reeve
Journal:  J Clin Pathol       Date:  2006-12-15       Impact factor: 3.411

5.  Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Authors:  A K Charles; K W Brown; P J Berry
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

6.  Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding.

Authors:  Q Zhan; I T Chen; M J Antinore; A J Fornace
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

7.  Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation.

Authors:  Qianghua Hu; Fei Gao; Weihua Tian; E Cristy Ruteshouser; Yaqing Wang; Alexander Lazar; John Stewart; Louise C Strong; Richard R Behringer; Vicki Huff
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

8.  Wilms' tumour protein Wt1 stimulates transcription of the gene encoding vascular endothelial cadherin.

Authors:  Karin M Kirschner; Lina K Sciesielski; Holger Scholz
Journal:  Pflugers Arch       Date:  2010-09-02       Impact factor: 3.657

9.  Fine structure analysis of the WT1 gene in sporadic Wilms tumors.

Authors:  R Varanasi; N Bardeesy; M Ghahremani; M J Petruzzi; N Nowak; M A Adam; P Grundy; T B Shows; J Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

10.  WNT5A is regulated by PAX2 and may be involved in blastemal predominant Wilms tumorigenesis.

Authors:  Yahya Tamimi; Usukuma Ekuere; Nicholas Laughton; Paul Grundy
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.